Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Baseline NSCLC cell lines compared to a reference mix consisting of 45 NSCLC cell lines

ABSTRACT: 34 NSCLC cell lines were transcriptionally profiled against a reference mix of 45 NSCLC cell lines to look subtype specific differential gene expression

ORGANISM(S): Homo sapiens

PROVIDER: GSE43567 | GEO | 2013/01/18

SECONDARY ACCESSION(S): PRJNA186732

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Baseline NSCLC cell lines compared to a reference mix consisting of 45 NSCLC cell lines

Project description:34 NSCLC cell lines were transcriptionally profiled against a reference mix of 45 NSCLC cell lines to look subtype specific differential gene expression 34 individual cell lines were compared to a reference mix consiting of 45 NSCLC cell lines

2013-01-18 | E-GEOD-43567 | biostudies-arrayexpress

Baseline NSCLC cell lines compared to a reference mix consisting of 45 NSCLC cell lines

Project description: Not available

| S-ECPF-GEOD-43567 | biostudies-other

Transcriptome in NSCLC cell lines

Project description:Transcriptome in NSCLC cell lines

| PRJNA808994 | ENA

Triple SILAC glycoproteomic analysis of NSCLC cell lines

Project description:Protein glycosylation plays a fundamental role in a multitude of biological processes, and the associated aberrant expression of glycoproteins in cancer has made them attractive targets as biomarkers and therapeutic targets. In this study, we examined differentially expressed glycoproteins in cell lines derived from three different states of lung tumorigenesis: an immortalized bronchial epithelial cell (HBE) line, a non-small cell lung cancer (NSCLC) cell line harboring an activation KRAS mutation and a NSCLC cell line harboring an EGFR activation deletion. Mutations in KRAS and EGFR are two common, distinct, non-overlapping genomic alterations in NSCLC. Using a Triple SILAC proteomic quantification strategy paired with hydrazide chemistry N-linked glycopeptide enrichment, we identified 118 quantifiable glycopeptides in the 3 cell lines derived from 82 glycoproteins. Proteomic profiling revealed that 27 (24%) of the glycopeptides overexpressed in both of the NSCLC cell lines with 6 of the glycopeptides overexpressed only in the EGFR mutant cells and 19 of the glycopeptides overexpressed only in the KRAS mutant cells.

2015-12-10 | PXD001999 | Pride

Transcriptome in NSCLC cell lines

Project description:Analysis of the whole transcriptome in 15 NSCLC cell lines of different origin

2022-05-18 | GSE197109 | GEO

Gefitinib sensitivity in NSCLC cell lines

Project description:Eleven NSCLC cell lines with widely divergent gefitinib sensitivities were compared using gene expression. Genes associated with gefitinib response were used to classify additional NSCLC lines with unknown gefitnib sensitivity. A subset of the test set data was tested for gefitinib sensitivity, and results correlated strongly with the gene expression-based predictions All eleven training set lines, and seven test set lines had both HGU133A and B chips done, while other test set lines had only HGU133As. Keywords: cell response comparison

2006-08-31 | GSE4342 | GEO

Triple SILAC glycoproteomic analysis of NSCLC cell lines

2016-03-10 | MSV000079569 | MassIVE

NSCLC cells treated with Gefitinib

Project description:About 10% of all NSCLC patients respond to gefitnib treatment and all of these patients will acquire resistance to the EGFR TKI. We used microarray to look at global gene expression changes in untreated cells vs gefitinib treated cells to identify key characters for the acquisition of resistance. NSCLC cells, H322c, were cultured 4 days in media containing 1?M gefitinib or 0.1% DMSO as a control. On day 4, RNA was extracted and submitted for microarray hybridization.

2011-01-27 | E-GEOD-23206 | biostudies-arrayexpress

NSCLC cells treated with Gefitinib

2011-01-27 | GSE23206 | GEO

Uncovering the divergent epigenetic background of KRAS-mutant NSCLC in mouse and human cell lines

Project description:Illumina miRNA-seq method to uncover the expression profile of NSCLC in-vitro experimental models consisting of cell lines A549, H460 compared to healthy BEAS-2B cell line, and lung tissue (NSCLC and paired normal) from urethane treated 6-week-old FVB/NJ mice. We aimed to uncover the divergent epigenetic background of KRAS-mutant NSCLC in mouse and human cell lines, extensively used as biological models in relevant research. To that end, we have comprehensively mapped the functional miRNA and lncRNA landscape of human (A549 and H460) and mouse (experimentally developed LUAD) NSCLC models and correlated current results with LRF/ZBTB7A expression

2023-12-25 | GSE251697 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data